echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > 2 Table Summary: How to choose the treatment drugs for non-tuberculous mycobacteria?

    2 Table Summary: How to choose the treatment drugs for non-tuberculous mycobacteria?

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The treatment of NTM lung disease should be considered in combination with pathogenic microorganisms, drug sensitivity, imaging findings and disease severity.
    Generally speaking, more than three drugs should be used at the same time to reduce induced drug resistance.
    After turning negative, she continued to use medication for 12 months.

    Therefore, the side effects of treatment will be more frequent, which affects compliance and treatment effect.

    The latest guidelines recommend that for patients with mild/moderate non-cavitary NTM lung disease and slower disease progression, it is more recommended to receive treatment 3 times a week instead of daily, and patients will be better tolerated.

    Please refer to the following two tables for the sensitivity of commonly used therapeutic drugs to different strains and the drug recommendations of the main strains of NTM lung disease: Table 1 Sensitivity of commonly used drugs to different NTM strains (click to view the larger image) Note: +++ is Strong antibacterial activity; ++ for general antibacterial activity; + for weaker antibacterial activity;-for drug resistance Table 2 Recommendations for medication of the main strains of NTM lung disease (click to view larger image) References: 1.
    Gill LI , Dominic C, Tiberi S.
    Atypical mycobacterial infections-management and when to treat.
    Curr Opin Pulm Med.
    2021 May 1;27(3):216-223.
    2.
    Chinese Medical Association Tuberculosis Branch.
    Nontuberculous Mycobacterial Diseases Guidelines for diagnosis and treatment (2020 edition)[J].
    Chinese Journal of Tuberculosis and Respiratory Medicine, 2020, 43(11):918-946.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.